• About Us
    • Overview
    • Contact
  • Technology
    • Overview
    • Platform
    • Publications
  • Programs
    • Avaximab™-TNF
    • Sildenafil Citrate
    • Research
  • Partners
    • Partners
  • Investors
    • Investors
  • Media
    • Press Releases
    • In The News

Technology

  • Overview
  • Publications

Publications

CCFA 2014 Poster: Modulation of inflammatory and disease biomarkers following 4 week treatment with AVX-470, an oral anti-TNF antibody, in ulcerative colitis patients

 

UEGW 2014 Presentation:AVX-470, an Orally Delivered Anti-TNF Antibody for Treatment of Acute Ulcerative Colitis: Results of a First-in-Human Trial

 

ACG 2014  Poster: Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of AVX-470, an Oral, Bovine-Derived Anti-TNF Antibody, in Patients with Active Ulcerative Colitis (UC): Initial Human Experience

 

Bhol et. al, “AVX-470: A Novel Oral Anti-TNF Antibody with Therapeutic
Potential in Inflammatory Bowel Disease” Inflamm Bowel Dis 2013;19:2273–2281.

Legal & Privacy    |    Sitemap    |    © 2016, Circle33, LLC